FDA Approves Sandoz’s Hyrimoz, Biosimilar to Humira, for Juvenile Arthritis, Other Diseases
News
The U.S. Food and Drug Administration has granted approval to Sandoz’s Hyrimoz (adalimumab-adaz), a biosimilar to Abbvie’s Humira. FDA approval includes indications for seven diseases, including juvenile idiopathic arthritis for patients ... Read more